Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications.
about
Kiwi genome provides insights into evolution of a nocturnal lifestyleCurrent loss-of-function mutations in the thyrotropin receptor gene: when to investigate, clinical effects, and treatmentHow genetic errors in GPCRs affect their function: Possible therapeutic strategiesAltered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus.PRR repeats in the intracellular domain of KISS1R are important for its export to cell membrane.GPCR and G proteins: drug efficacy and activation in live cells.Chaperoning G protein-coupled receptors: from cell biology to therapeuticsIpsen 5i is a Novel Potent Pharmacoperone for Intracellularly Retained Melanocortin-4 Receptor Mutants.Defect in MAPK signaling as a cause for monogenic obesity caused by inactivating mutations in the melanocortin-4 receptor gene.In silico mutagenesis: a case study of the melanocortin 4 receptorMutations that silence constitutive signaling activity in the allosteric ligand-binding site of the thyrotropin receptor.Functional studies on twenty novel naturally occurring melanocortin-4 receptor mutations.Biased signaling in naturally occurring mutations in human melanocortin-3 receptor gene.G protein-coupled receptors involved in GnRH regulation: molecular insights from human disease.An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations.The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.Functions of DPLIY motif and helix 8 of human melanocortin-3 receptor.Study of V2 vasopressin receptor hormone binding site using in silico methods.Functional characterization of nine novel naturally occurring human melanocortin-3 receptor mutations.Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targetsAutoimmune disease-associated histamine receptor H1 alleles exhibit differential protein trafficking and cell surface expression.A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization.Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics.A cell surface inactive mutant of the human lutropin receptor (hLHR) attenuates signaling of wild-type or constitutively active receptors via heterodimerization.TACR3 mutations disrupt NK3R function through distinct mechanisms in GnRH-deficient patients.Disease-causing mutation in GPR54 reveals the importance of the second intracellular loop for class A G-protein-coupled receptor function.Functions of acidic transmembrane residues in human melanocortin-3 receptor binding and activation.Effect of mutations in putative hormone binding sites on V2 vasopressin receptor function.V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.Research resource: Update and extension of a glycoprotein hormone receptors web applicationFunctional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients.Mutation-Induced Functional Alterations of CCR6.Intracellular Trafficking of Gonadotropin Receptors in Health and Disease.Pharmacoperones for Misfolded Gonadotropin Receptors.Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.Pharmacological Chaperones: Potential for the Treatment of Hereditary Diseases Caused by Mutations in G Protein-Coupled Receptors
P2860
Q21146631-5847C21A-9B1D-41EC-A95D-F3468A21DE9CQ27005599-EB515DD6-6A51-4270-8409-B2AE519B3BF2Q28646207-85494F36-80ED-4DDF-941C-3C242D02E3BBQ33632079-54FF0515-9EFE-480F-B297-7BA75B0FD21EQ33633147-CD306799-405E-4C33-ABB9-37194D91FBC4Q33642442-E684F3FF-5E8E-483E-A4EA-61088AF32D99Q33927508-B0018516-5621-4876-9D6A-44D8A7EE3A48Q33997482-61AD21F8-14D6-43E6-B2D9-CAD4B1064764Q34365195-35F99A97-A41A-44C7-AC11-A437BF376E1EQ34979349-764270D5-D96A-4882-B2D2-F149388DB4DBQ34997058-60170C9C-A0D3-4296-8CD1-7B2D7575487DQ35162218-FD0AE0EB-B753-49B3-A0D2-A083A98DBF90Q35197511-CFA858EB-E1DE-4619-A230-FC7F73512931Q35256585-92988ECC-3A81-4E10-8958-5E723C38F649Q35720141-B3AD222D-E73F-4EFE-A3BC-6C39B2134B82Q36003378-54090039-5FD3-48E8-88F2-948ACE7544E1Q36006349-C78B3984-06F6-4B5F-94E6-63132B7914AEQ36216720-A089778D-A849-4922-8A6F-74A53DCBA7E2Q36301643-933D5B28-0B83-429D-A9EA-9D97F3B12349Q36316001-8E870545-7D45-4230-A1C4-4F463C3473BBQ36891674-A9CA1375-44C7-4A6E-8F9C-160EAE503AFCQ36983708-F1EF09F6-690F-477C-8B17-E2456673035EQ37157903-E97BC94A-2CB1-418C-B3B0-9094EA706A56Q37327629-B61C35E0-D424-4784-AE0A-E41F8A45BA5BQ37657090-935AA185-BE85-4AD8-AD87-0F2D68F4C7F5Q39943167-C40D69C7-9A4B-440A-BF06-75193C159EDFQ39963364-737BEBBC-3B56-4C79-B076-A5473DB8A704Q40281619-990E6923-3F27-43FD-8852-A6C55EB1EFA1Q40649339-40DADF78-5219-43CF-89A8-143A69CE470FQ42236936-64E55167-8E4C-494C-AA39-12533207D790Q42239787-1585C167-FC05-4CFD-92A4-B88F3BFF54DFQ42501097-6BC896A7-4210-4124-B516-54C7ECC6E45AQ47612221-DCAE0E96-78C4-49E4-A27B-26E02E6F1136Q47635965-7C110038-143E-4015-BA82-C2BB3947BB92Q50014672-F8FACE39-1A2F-4663-BD63-FEC1D3F1E31EQ56648598-A7E294F0-A0CF-484E-AEAA-BC6DF5E16FAF
P2860
Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Inactivating mutations of G pr ...... and therapeutic implications.
@ast
Inactivating mutations of G pr ...... and therapeutic implications.
@en
Inactivating mutations of G pr ...... and therapeutic implications.
@nl
type
label
Inactivating mutations of G pr ...... and therapeutic implications.
@ast
Inactivating mutations of G pr ...... and therapeutic implications.
@en
Inactivating mutations of G pr ...... and therapeutic implications.
@nl
prefLabel
Inactivating mutations of G pr ...... and therapeutic implications.
@ast
Inactivating mutations of G pr ...... and therapeutic implications.
@en
Inactivating mutations of G pr ...... and therapeutic implications.
@nl
P1476
Inactivating mutations of G pr ...... s and therapeutic implications
@en
P2093
Ya-Xiong Tao
P304
P356
10.1016/J.PHARMTHERA.2006.02.008
P50
P577
2006-04-17T00:00:00Z